Vaginal, Urethral, Uterine Patents (Class 424/430)
-
Publication number: 20030031702Abstract: A pharmaceutical product comprising isotretinoin and a contraceptive.Type: ApplicationFiled: July 27, 2001Publication date: February 13, 2003Inventor: Leonard L. Mazur
-
Patent number: 6495157Abstract: A highly storage-stable composition for vaginal administration of clindamycin is disclosed which is useful for the treatment of bacterial vaginosis. The composition is a vaginal suppository containing an antimicrobially effective amount of clindamycin dispersed in a Hard Fat NF suppository base. Hard Fat NF suppository bases provide a clindamycin product having long term storage stability while providing efficacy against bacterial vaginosis which is equivalent to clindamycin vaginal creams.Type: GrantFiled: July 20, 2000Date of Patent: December 17, 2002Assignee: Pharmacia & Upjohn CompanyInventors: Lorraine Elisabeth Pena, Phil Bryan Bowman, Robert Shih-Liang Chao, Carolyn V. Pesheck
-
Patent number: 6479045Abstract: The present invention concerns compositions and methods for preventing miscarriage and premature labor, and for treating and preventing Bacterial Vaginosis using a pH-buffering polymer. The present invention further concerns formulating such a composition or method in such a way as to provide therapeutically sufficient levels of the composition to a patient in need thereof.Type: GrantFiled: December 21, 2000Date of Patent: November 12, 2002Assignee: Columbia Laboratories, Inc.Inventors: William J. Bologna, Howard L. Levine
-
Patent number: 6479232Abstract: A method for screening candidate antimicrobial compounds is described that utilizes a human vaginal xenograft engrafted in a non-human host. The method may be performed by using pathogen inoculated human vaginal xenografts in order to screen a wide range of candidate antimicrobials administered topically or systemically.Type: GrantFiled: July 24, 2000Date of Patent: November 12, 2002Assignee: The Pennsylvania State UniversityInventors: Mary K. Howett, John W. Kreider
-
Patent number: 6476074Abstract: Compositions and methods for treatment of impotence or erectile dysfunction employ prostaglandins that are selective EP2 or EP4 prostanoid receptor agonists. The compositions can be formulated for intracavernous injection, or for transurethral or transdermal application.Type: GrantFiled: April 10, 2000Date of Patent: November 5, 2002Assignee: Synphora ABInventors: Johan Stjernschantz, Bahram Resul
-
Publication number: 20020150605Abstract: This invention provides to a novel pharmaceutical preparation for the treatment of gynecological diseases. The pharmaceutical preparation according to the invention comprises a therapeutic drug for the intrauterine, intravaginal or intrapelvic administration, or for the administration into the ovarian endometrioma, and a biodegradable polymer comprising a chemically modified hyaluronic acid or a salt thereof prepared by O-acylating, alkoxylating or crosslinking a complex of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent. The preparation of the invention is preferably administered intrauterine, intravaginal, intrapelvic, and intratumor cavity.Type: ApplicationFiled: March 28, 2002Publication date: October 17, 2002Inventors: Nobuhiko Yui, Kouichi Murakami, Tooru Ooya, Ikuo Sato
-
Patent number: 6464670Abstract: A urethral suppository having a shaft shaped for cooperating with the action of the periurethral musculature to retain the suppository within the urethra, and having a knob extending from an end of the shaft sized to prevent over insertion of the suppository. A method of delivering one or more therapeutic agents to the urethra and associated structures, the method involving insertion of the urethral suppository into the urethra.Type: GrantFiled: November 10, 1999Date of Patent: October 15, 2002Assignee: BioMed Innovations, LLCInventor: S. Grant Mulholland
-
Patent number: 6464999Abstract: Disclosed herein are bioadhesive medical devices formed in whole or in part of a cohesive bioadhesive copolymer of a carboxyl functional monomer and a hydrophobic functional monomer.Type: GrantFiled: October 20, 1999Date of Patent: October 15, 2002Assignee: Galt IncorporatedInventors: Peter P. Huo, Sheila Wallin
-
Patent number: 6458346Abstract: Microbicidal and spermicidal devices, methods, and compositions containing sodium dodecyl sulfate or related anionic surfactants as active ingredients for the prevention and control of pregnancy and sexually transmitted disease, including conditions caused by non-enveloped viruses such as human papilloma virus.Type: GrantFiled: May 14, 2001Date of Patent: October 1, 2002Assignee: The Pennsylvania State UniversityInventors: Mary K. Howett, John W. Krieder
-
Patent number: 6455060Abstract: The present invention provides novel compositions and methods for using the S(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.Type: GrantFiled: March 5, 2001Date of Patent: September 24, 2002Assignee: Somerset Pharmaceuticals, Inc.Inventor: Anthony R. DiSanto
-
Patent number: 6455034Abstract: Methods, compositions and products are described which inhibit the development of odor in excreted body fluids by odor-causing cations.Type: GrantFiled: October 13, 1994Date of Patent: September 24, 2002Assignee: McNeil-PPC, Inc.Inventor: Fred H. Steiger
-
Patent number: 6455246Abstract: A method for screening candidate antimicrobial compounds is described that utilizes a human vaginal xenograft engrafted in a non-human host. The method may be performed by using pathogen inoculated human vaginal xenografts in order to screen a wide range of candidate antimicrobials administered topically or systemically.Type: GrantFiled: July 24, 2000Date of Patent: September 24, 2002Assignee: The Pennsylvania State UniversityInventors: Mary K. Howett, John W. Kreider
-
Patent number: 6451779Abstract: A composition with three hormone components is administered to a mammal to cause the suppression or cessation of the menstruation cycle. Alternatively, it can be administered for treatment of tumors of the mammary gland. The composition contains at least a synthetic estrogen, a biogenetic estrogen, and a gestagen. Alternatively, the composition can include hormones which upon ingestion are metabolized to the above-mentioned hormones.Type: GrantFiled: April 10, 2000Date of Patent: September 17, 2002Inventor: Rolf-Dieter Hesch
-
Patent number: 6444224Abstract: Disclosed herein is a porcine intra-vaginal device of a shape and size adapted to be positionable in the vaginal tract across the hymenal ring of a target animal (e.g., a gilt) to extend to both sides of the hymenal ring of the animal. The device once inserted delivers progesterone from a progesterone impreganated matrix on either side of the hymenal ring, the progesterone releasing surface being at least 150 cm2 in total area. Variable geometry means (preferably for vestibular engagement) ensure retention of the devices (e.g., for at least 7 to 14 days) where, in the preferred device, the progesterone load of from 1.9 to 2.5 g within 1.2 mm of the release surface can, by maintaining a progesterone blood plasma level (equating to a progestrone blood plasma level in excess of 4 ng/mL measured in an ovariectomised animal), ensure or prompt the onset of oestrus within 3 to 5 days after device removal.Type: GrantFiled: March 2, 2000Date of Patent: September 3, 2002Assignee: InteragInventors: Michael John Rathbone, Shane Burccraff, James Frederick Pharaoh
-
Patent number: 6436633Abstract: A method for screening candidate antimicrobial compounds is described that utilizes a human vaginal xenograft engrafted in a non-human host. The method may be performed by using pathogen inoculated human vaginal xenografts in order to screen a wide range of candidate antimicrobials administered topically or systemically.Type: GrantFiled: October 22, 1999Date of Patent: August 20, 2002Assignee: The Pennsylvania State UniversityInventors: John W. Kreider, Mary K. Howett
-
Patent number: 6432440Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, comprising a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.Type: GrantFiled: January 20, 2000Date of Patent: August 13, 2002Assignee: West Pharmaceutical Services Drug Delivery & Clinical Research Centre LimitedInventors: Peter James Watts, Lisbeth Illum
-
Patent number: 6428784Abstract: A composition for treatment of bacterial infections of the vagina is disclosed which comprises a lytic enzyme composition specific for the infecting bacteria, and a carrier for delivering said lytic enzyme. The lytic enzyme is which is specific for the group B Streptococcus, is genectically coded for by a specific bacteriophage.Type: GrantFiled: September 28, 2000Date of Patent: August 6, 2002Assignee: New Horizons Diagnostics CorpInventors: Vincent Fischetti, Lawrence Loomis
-
Patent number: 6426084Abstract: Methods for treating specific patient groups for sexual dysfunction are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions in patients who are free of cardiac disease and/or who have not been given organic nitrates.Type: GrantFiled: June 19, 2000Date of Patent: July 30, 2002Inventor: Neal R. Cutler
-
Patent number: 6420336Abstract: The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.Type: GrantFiled: October 27, 1999Date of Patent: July 16, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Michael R. Boyd
-
Patent number: 6416780Abstract: This invention relates to an intravaginal shell or core drug delivery device suitable for administration to female humans or animals comprises testosterone or a testosterone precursor in a polymer matrix, surrounded by a sheath, and is capable of releasing the testosterone or testosterone precursor in a substantially zero-order pattern on a daily basis for at least three weeks. The device is intended to restore circulating testosterone levels to the normal physiol, range or to induce supratherapeutic testosterone levels.Type: GrantFiled: May 1, 2000Date of Patent: July 9, 2002Assignee: Galen (Chemicals) LimitedInventors: Clare Passmore, Claire Gilligan
-
Patent number: 6416779Abstract: Devices, methods, and compositions for treating vaginal fungal, bacterial, viral and parasitic infections by intravaginal or transvaginal administration of therapeutic and/or palliative antifungal, antibacterial, antiviral or parasiticidal drugs to the vagina or to the uterus.Type: GrantFiled: July 11, 2000Date of Patent: July 9, 2002Assignee: UMD, Inc.Inventors: Merida A. D'Augustine, James H. Liu, Donald C. Harrison
-
Patent number: 6416778Abstract: Formulations have been developed for regional delivery of drugs, for example, into a cavity such as the pelvic region, peritoneal region, or directly on organs of interest. Regional delivery increases comfort and bioavailability of the drug, resulting in rapid and relatively high blood levels in the regions to be treated in the substantial absence of side effects due to the high levels required for efficacy following systemic delivery. In the preferred embodiment, these formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The drug formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.Type: GrantFiled: July 23, 1999Date of Patent: July 9, 2002Assignee: FemmePharmaInventors: Vanaja V. Ragavan, Gerianne M. DiPiano
-
Patent number: 6406710Abstract: The present invention relates to complexes between (1) a target-binding moiety; (2) a cavity-forming moiety; and (3) a pharmacological compound to be delivered to a target, wherein the pharmacological compound is buried inside of the cavity-forming moiety, but not covalently bound to either the target-binding moiety or the cavity-forming moiety. The complexes of thus invention may be used as to deliver a pharmacological compound to cells, tissues, organs, viruses, microorganisms or other surfaces that are characterized by an entity that binds the target-binding moiety portion of the complex. The present invention also relates to pharmaceutical compositions comprising the non-covalent complexes of this invention. The invention also relates to methods of delivering a pharmacological compound to a target in a patient. The present invention also relates to the use of the complexes of this invention for the separation of chemical entities from their chiral forms or contaminants.Type: GrantFiled: July 16, 1998Date of Patent: June 18, 2002Inventor: Nikos Panayotatos
-
Patent number: 6403758Abstract: Crosslinked compositions formed from a water-insoluble copolymer are disclosed. These compositions are copolymers having a bioresorbable region, a hydrophilic region and at least two crosslinkable functional groups per polymer chain. These compositions are able to form hydrogels in aqueous environments when crosslinked. These hydrogels are good sealants for implantable prostheses when in contact with an aqueous environment. In addition, such hydrogels can be used as delivery vehicles for therapeutic agents.Type: GrantFiled: November 8, 1999Date of Patent: June 11, 2002Assignee: Scimed Life Systems, Inc.Inventor: Gary L. Loomis
-
Patent number: 6403113Abstract: Anti-microbic copolymers and derivatives thereof are used in methods for controlling odor in hygienic articles. The copolymers comprise at least two different ethylenically unsaturated monomers.Type: GrantFiled: January 19, 2000Date of Patent: June 11, 2002Assignee: The Procter & Gamble CompanyInventor: Italo Corzani
-
Patent number: 6387378Abstract: Disclosed herein is a device for storing and/or delivering an effective amount of biological or pharmaceutical material to an animal comprising a tube disposed to contain said biological or pharmaceutical material and sealed at its ends and adapted to provide an opening through which the biological or pharmaceutical material exits and is administered to an intended site of the animal.Type: GrantFiled: September 9, 1993Date of Patent: May 14, 2002Inventors: George P. Shibley, Karen K. Brown, Leszek J. Choromanski, Sharon A. Bryant
-
Patent number: 6383514Abstract: A hypocholesterolemic composition, for use in reducing serum cholesterol levels in warm-blooded organisms, the composition containing: (a) a phytostanol ester and (b) a tocopherol.Type: GrantFiled: May 20, 1999Date of Patent: May 7, 2002Assignee: Henkel Kommanditgesellschaft auf AktienInventors: Norbert Weitkemper, Bernd Fabry
-
Patent number: 6368586Abstract: Methods and compositions are provided for enhancing the bioadhesive properties of polymers used in drug delivery devices. The bioadhesive properties of a polymer are enhanced by incorporating a anhydrideoligome into the polymer to enhance the ability of the polymer to adhere to a tissue surface such as a mucosal membrane. Anhydrideoligomes which enhance the bioadhesive properties of a polymer include water-insoluble anhydrideoligomes such as water-insoluble metal oxides, including oxides of calcium, iron, copper and zinc. The anhydrideoligomes can be incorporated within a wide range of polymers including proteins, polysaccharides and synthetic biocompatible polymers. In one embodiment, metal oxides can be incorporated within polymers used to form or coat drug delivery devices, such as microspheres, which contain a drug or diagnostic agent.Type: GrantFiled: March 27, 2000Date of Patent: April 9, 2002Assignee: Brown University Research FoundationInventors: Jules S. Jacob, Edith Mathiowitz
-
Publication number: 20020018796Abstract: An thermally sterilized bone paste useful in the orthopedic arts, for example in the repair of non-union fractures, periodontal ridge augmentation, craniofacial surgery, implant fixation, impaction grafting, or any other procedure in which generation of new bone is deemed necessary, is provided by a composition comprising a substantially bioabsorbable osteogenic compound in a matrix of 11-19%, and preferably about 15-19% (w/w) or thermally sterilized gelatin. In various embodiments, the osteogenic compound is selected from (i) demineralized bone matrix (DBM); (ii) bioactive glass ceramic, BIOGLASS®, bioactive ceramic, calcium phosphate ceramic, hydroxyapatite, hydroxyapatite carbonate, corraline hydroxyapatite, calcined bone, tricalcium phosphate, or like material; (iii) bone morphogenetic protein, TGF-&bgr;, PDGF, or mixtures thereof, natural or recombinant; and (iv) mixtures of (i)-(iii).Type: ApplicationFiled: January 28, 1998Publication date: February 14, 2002Inventor: JOHN F. WIRONEN
-
Publication number: 20020006431Abstract: The invention relates to disposable absorbent articles containing an additive to control odors associated with bodily fluids. The invention is particularly useful in articles used to manage urine and menstrual fluids. The single additive provides both a pleasant aroma and antimicrobial activity.Type: ApplicationFiled: July 6, 2001Publication date: January 17, 2002Inventor: Priscilla M. Tramontana
-
Patent number: 6328991Abstract: A chemical composition, method and product for administration into the vaginal canal. The composition, method and product are effective in preventing the spread of sexually transmitted diseases, including the spread of AIDS.Type: GrantFiled: November 30, 1999Date of Patent: December 11, 2001Inventor: John Myhling
-
Patent number: 6322804Abstract: An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual.Type: GrantFiled: May 2, 2000Date of Patent: November 27, 2001Assignee: Neurotech S.A.Inventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Scharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasconcellos, Michael J. Lysaght, Frank T. Gentile
-
Patent number: 6316522Abstract: Crosslinked compositions formed from water-insoluble copolymers are disclosed. These compositions are copolymers having a bioresorbable region, a hydrophilic region and at least two cross-linkable functional groups per polymer chain. Crosslinking of these polymers can be effected in solution in organic solvents or in solvent-free systems. If crosslinking occurs in a humid environment, a hydrogel will form. If crosslinking occurs in a non-humid environment, a xerogel will form which will form a hydrogel when exposed to a humid environment and the resulting crosslinked materials form hydrogels when exposed to humid environments. These hydrogels are useful as components in medical devices such as implantable prostheses. In addition, such hydrogels are useful as delivery vehicles for therapeutic agents and as scaffolding for tissue engineering applications.Type: GrantFiled: September 14, 1999Date of Patent: November 13, 2001Assignee: Scimed Life Systems, Inc.Inventors: Gary L. Loomis, D. Christian Lentz
-
Patent number: 6312735Abstract: Disclosed here is a method for the removal of all types of human and animal skin warts using a technique of cauterization wherein slaked lime is applied to wart and then the surface of wart is scratched by using the stem of betel leaf.Type: GrantFiled: February 9, 2001Date of Patent: November 6, 2001Inventors: Sarfaraz K. Niazi, Riaz K. Niazi
-
Publication number: 20010028893Abstract: The present invention provides a method of delivering an emulsion or suspension containing a supersaturated gas into a gas-depleted environment. The method generally comprises the steps of preparing an emulsion or suspension, exposing the emulsion or suspension to a gas at a pressure greater than 2 bar, and delivering the emulsion or suspension to a gas-depleted environment at ambient pressure.Type: ApplicationFiled: May 25, 2001Publication date: October 11, 2001Inventor: J. Richard Spears
-
Patent number: 6299894Abstract: The invention relates to a delivery device for the controlled release of the therapeutically active agent gestodene, over a prolonged period of time, at a release rate of 0,1-300 &mgr;g/day, said device comprising a core comprising at least said therapeutically active agent, and a membrane encasing said core wherein said membrane is made of an elastomer. According to the invention, the elastomer is a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units, and the release rate of said therapeutically active agent of said delivery device is regulated by the amount of said 3,3,3-trifluoropropyl groups.Type: GrantFiled: May 10, 2000Date of Patent: October 9, 2001Assignee: Leiras OyInventors: Tommi Markkula, Juha Ala-Sorvari, Harri Jukarainen, Matti Lehtinen, Jarkko Ruohonen
-
Patent number: 6294188Abstract: The first aspect of the invention relates to a method of inducing changes in the cervical mucus of a person to achieve a contraceptive effect, and wherein the method involves administering to the person an effective amount of ebrotidine sufficient to achieve a contraceptive effect. The second aspect of the invention involves a method for treating atrophic vaginitis urinary incontinence and their associated signs and symptoms, in a person, the method involves administering to the person an effective mount of an agent sufficient to treatment of atrophic vaginitis, the agent being selected from a group consisting of stimulants or antagonists, purinergic receptors, a sodium ion update agents and an anion secretion inhibitors.Type: GrantFiled: July 2, 1999Date of Patent: September 25, 2001Assignee: Aviana BioPharm Inc.Inventors: Vanaja V. Ragavan, Alan Laties
-
Patent number: 6287589Abstract: A contraceptive method of inducing ovulation in induced ovulation mammals, in particular the female cat, by stimulating mainly the cervical region of the vagina to trigger a cascade of hormonal reactions to cause ovulation and pseudo-pregnancy to eliminate the unwanted behavior of female cats in heat. The treatment consists in the introduction of an ovulator inside the vaginal cavity of the animal. This apparatus is similar in shape and size to the penis of a cat, is made of a soft flexible material and is safe and easy to clean. The method imitates the sexual behavior of cats by causing a repeated number of brief stimulations at the peak of the estrus cycle.Type: GrantFiled: September 30, 1998Date of Patent: September 11, 2001Inventor: Richard Drapeau
-
Patent number: 6284261Abstract: The invention relates to disposable absorbent articles containing an additive to control odors associated with bodily fluids. The invention is particularly useful in articles used to manage urine and menstrual fluids. The single additive provides both a pleasant aroma and antimicrobial activity.Type: GrantFiled: May 27, 1999Date of Patent: September 4, 2001Assignee: McNeil-PPC, Inc.Inventor: Priscilla M. Tramontana
-
Publication number: 20010016716Abstract: A method of delivering one or more therapeutic agents comprising providing a suppository comprising one or more therapeutic agents and a biocompatible carrier medium and shaped to be capable of cooperating with the periurethral musculature to retain the suppository in place in the urethra, inserting the suppository into the urethra, and retaining the suppository within the urethra by the action of the periurethral musculature for a period of time sufficient to permit the therapeutic agent to diffuse substantially into the urethra, the referred suppository comprising a shaft having a first end and a second end and shaped to be capable of cooperating with the action of the periurethral musculature to retain the suppository within the urethra and a substantially ellipsoidal knob extending from the second end of the shaft and sized to prevent insertion into the urethra.Type: ApplicationFiled: September 9, 1998Publication date: August 23, 2001Inventor: S. GRANT MULHOLLAND
-
Patent number: 6270789Abstract: The present invention provides a base for suppository comprising oily or fatty base and polyethlene. The suppository prepared by the use of the base of the present invention has superior heat resistance which should not cause quality deterioration such as deformation and cracks, and shows good release, internal absorbability, safety and like compared to those of the suppositories used thus so far in the applied region.Type: GrantFiled: January 19, 2000Date of Patent: August 7, 2001Assignee: Amato Pharmaceutical Products, Ltd.Inventors: Teruyuki Sameshima, Kengo Omachi, Izumi Fukuda
-
Patent number: 6264973Abstract: A novel and useful apparatus for delivering an anesthetic locally to the cervical region of a female is provided, wherein the apparatus comprises a ring having a surface and at least one depression on the surface. An anesthetic composition comprising an anesthetic agent and an excipient are placed within the at least one depression. The ring is comprised of a pharmaceutically acceptable inert material that is biocompatible. Furthermore, the ring is of sufficient size such that it can be inserted into the vaginal canal of a female. In the vaginal canal, the anesthetic agent is immediately released from the anesthetic composition and directly anesthetizes the cervical region.Type: GrantFiled: August 26, 1999Date of Patent: July 24, 2001Assignee: FEI Enterprises, Ltd.Inventors: Anu Mahashabde, Martha Francine Kay, Louis J. Mestichelli, Ann Elizabeth Gooding, Suzanne Wilford Ruth
-
Patent number: 6264972Abstract: A tampon constructed of a foamed plastic polyvinyl acetal material with an outer skin and a less dense inner central portion having a greater large pore and common pore density. The polyvinyl acetal material is impregnated with glycerine in a range of 2% to 20% concentration in a water carrier to present a soft compliant tampon.Type: GrantFiled: November 10, 1999Date of Patent: July 24, 2001Assignee: Tolland Development Company, LLCInventor: Thomas J. Drury
-
Patent number: 6258374Abstract: The invention provides a pharmaceutical composition for rectal or vaginal administration which comprises at least two parts wherein the composition comprises (i) two or more physiologically acceptable substances each in separate parts of the composition which are such that on admixture they react to produce a physiologically acceptable gas; (ii) in at least one part of the composition a polymer stabiliser which is adapted to facilitate the formation of a water-soluble collapsible foam structure; and (iii) in at least one part of the composition a pharmaceutically active substance; an its use in the treatment or prophylaxis of disorders of the intestines, rectum or vagina.Type: GrantFiled: September 24, 1998Date of Patent: July 10, 2001Assignee: Astra AktiebolagInventors: Stefan Friess, Harald Heckenmüller, Heike Kublik, Oliver Szambien
-
Patent number: 6248363Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.Type: GrantFiled: November 23, 1999Date of Patent: June 19, 2001Assignee: Lipocine, Inc.Inventors: Mahesh V. Patel, Feng-Jing Chen
-
Patent number: 6248324Abstract: The present invention discloses a composition for dermatological infections by the use of a lytic enzyme in a carrier suitable for topical application to dermal tissues. The method for the treatment of dermatological infections comprises administering a composition comprising effective amount of a therapeutic agent, with the therapeutic agent comprising a lytic enzyme produced by infecting a bacteria with phage specific for that bacteria.Type: GrantFiled: September 28, 2000Date of Patent: June 19, 2001Inventors: Vincent Fischetti, Lawrence Loomis
-
Patent number: 6248358Abstract: A bioadhesive tablet wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the tablet, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the tablet is available for absorption (bioavailable).Type: GrantFiled: August 23, 1999Date of Patent: June 19, 2001Assignee: Columbia Laboratories, Inc.Inventors: William J. Bologna, Howard L. Levine, Philippe Cartier, Dominique de Ziegler
-
Patent number: 6224894Abstract: The present invention describes a polyoxaester copolymer and blends thereof that may be used to produce hydrogels, surgical devices such as sutures, sutures with attached needles, molded devices, drug matrices, adhesives, sealants and the like. The invention also contemplates a process for producing these polyesters. The polyoxaester copolymers of the present invention are formed from a first divalent repeating unit of formula IA: [—O—C(O)—R30—C(O)—] IA a second divalent repeating unit of the formula IB: [O—C(O)—C(R1)(R2)—O—R3—O—C(R′1)(R′2)—C(O)—] IB and a third repeating unit selected from the group of formulas consisting of: [—O—R4—]A, II [—O—R5—C(O)—]B, III ([—O—R5—C(O)]P—O—)LG XI and combinations thereof.Type: GrantFiled: August 11, 2000Date of Patent: May 1, 2001Assignee: Ethicon, Inc.Inventors: Dennis D. Jamiolkowski, Rao S. Bezwada
-
Patent number: 6221401Abstract: The present invention provides a bilayer structure for encapsulating multiple containment units. These containment units can attach or contain therapeutic or diagnostic agents that can be released through the bilayer structure. A suitable example of such a containment unit is a unilamellar or multilamellar vesicle.Type: GrantFiled: August 24, 1998Date of Patent: April 24, 2001Assignee: The Regents of the University of CaliforniaInventors: Joseph Zasadzinski, Scott Walker, Michael Kennedy
-
Patent number: 6214379Abstract: The present disclosure relates to novel dosage forms, drug delivery regimens, methods and pharmaceutical compositions which optimize the therapeutic effects of active therapeutic substances through the application of the concept of uneven dosing.Type: GrantFiled: June 1, 1999Date of Patent: April 10, 2001Assignee: KV Pharmaceutical CompanyInventor: Victor M. Hermelin